Literature DB >> 36219319

The miR-429 suppresses proliferation and migration in glioblastoma cells and induces cell-cycle arrest and apoptosis via modulating several target genes of ERBB signaling pathway.

Fatemeh Gheidari1,2, Ehsan Arefian3,4, Fatemeh Saadatpour5, Mahboubeh Kabiri1, Ehsan Seyedjafari1, Ladan Teimoori-Toolabi6, Masoud Soleimani7.   

Abstract

BACKGROUND: Glioblastoma multiforme (GBM) is an aggressive and lethal brain cancer, which is incurable with standard cancer treatments. miRNAs have great potential to be used for gene therapy due to their ability to modulate several target genes simultaneously. We found miR-429 is downregulated in GBM and has several predicted target genes from the ERBB signaling pathway using bioinformatics tools. ERBB is the most over-activated genetic pathway in GBM patients, which is responsible for augmented cell proliferation and migration in GBM. METHODS AND
RESULTS: Here, miR-429 was overexpressed using lentiviral vectors in U-251 and U-87 GBM cells and it was observed that the expression level of several oncogenes of the ERBB pathway, EGFR, PIK3CA, PIK3CB, KRAS, and MYC significantly decreased, as shown by real-time PCR and western blotting. Using the luciferase assay, we showed that miR-429 directly targets MYC, BCL2, and EGFR. In comparison to scrambled control, miR-429 had a significant inhibitory effect on cell proliferation and migration as deduced from MTT and scratch wound assays and induced cell-cycle arrest and apoptosis in flow cytometry.
CONCLUSIONS: Altogether, miR-429 seems to be an efficient suppressor of the ERBB genetic signaling pathway and a potential therapeutic for GBM.
© 2022. The Author(s), under exclusive licence to Springer Nature B.V.

Entities:  

Keywords:  EGFR; ERBB pathway; Glioblastoma multiforme; MYC; Migration; Proliferation; miR-429

Year:  2022        PMID: 36219319     DOI: 10.1007/s11033-022-07903-2

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.742


  52 in total

Review 1.  The functions of animal microRNAs.

Authors:  Victor Ambros
Journal:  Nature       Date:  2004-09-16       Impact factor: 49.962

Review 2.  Nanomedicine to overcome radioresistance in glioblastoma stem-like cells and surviving clones.

Authors:  Delphine Séhédic; Annabelle Cikankowitz; François Hindré; François Davodeau; Emmanuel Garcion
Journal:  Trends Pharmacol Sci       Date:  2015-03-20       Impact factor: 14.819

Review 3.  Epidemiology and molecular pathology of glioma.

Authors:  Judith A Schwartzbaum; James L Fisher; Kenneth D Aldape; Margaret Wrensch
Journal:  Nat Clin Pract Neurol       Date:  2006-09

Review 4.  Sui generis: gene therapy and delivery systems for the treatment of glioblastoma.

Authors:  J Robert Kane; Jason Miska; Jacob S Young; Deepak Kanojia; Julius W Kim; Maciej S Lesniak
Journal:  Neuro Oncol       Date:  2015-03       Impact factor: 12.300

Review 5.  Glioblastoma multiforme: Pathogenesis and treatment.

Authors:  Constantinos Alifieris; Dimitrios T Trafalis
Journal:  Pharmacol Ther       Date:  2015-05-02       Impact factor: 12.310

Review 6.  Effective treatment of glioblastoma requires crossing the blood-brain barrier and targeting tumors including cancer stem cells: The promise of nanomedicine.

Authors:  Sang-Soo Kim; Joe B Harford; Kathleen F Pirollo; Esther H Chang
Journal:  Biochem Biophys Res Commun       Date:  2015-06-24       Impact factor: 3.575

7.  CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012-2016.

Authors:  Quinn T Ostrom; Gino Cioffi; Haley Gittleman; Nirav Patil; Kristin Waite; Carol Kruchko; Jill S Barnholtz-Sloan
Journal:  Neuro Oncol       Date:  2019-11-01       Impact factor: 12.300

Review 8.  The advance of application for microRNAs in cancer gene therapy.

Authors:  Guanghua Yang; Baobing Yin
Journal:  Biomed Pharmacother       Date:  2013-10-14       Impact factor: 6.529

Review 9.  Glioblastoma multiforme: a review of where we have been and where we are going.

Authors:  Cory Adamson; Okezie O Kanu; Ankit I Mehta; Chunhui Di; Ningjing Lin; Austin K Mattox; Darell D Bigner
Journal:  Expert Opin Investig Drugs       Date:  2009-08       Impact factor: 6.206

10.  Discovering the first microRNA-targeted drug.

Authors:  Morten Lindow; Sakari Kauppinen
Journal:  J Cell Biol       Date:  2012-10-29       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.